Object. Local tumor control, patient survival, and treatment failure outcom
es were analyzed to assess treatment efficacy in 58 patients in whom fracti
onated proton radiation therapy (RT) was administered for skull base chordo
mas and chondrosarcomas.
Methods. Between March 1992 and January 1998, a total of 58 patients who co
uld be evaluated were treated for skull base tumors, 33 for chordoma and 25
for chondrosarcoma. Following various surgical procedures, residual tumor
was detected in 91% of patients; 59% demonstrated brainstem involvement. Ta
rget dosages ranged from 64.8 and 79.2 (mean 70.7) Co Gy equivalent. The ra
nge of follow up was 7 to 75 months (mean 33 months).
In 10 patients (17%) the treatment failed locally, resulting in local contr
ol rates of 92% (23 of 25 patients) for chondrosarcomas and 76% (25 of 33 p
atients) for chordomas. Tumor volume and brainstem involvement influenced c
ontrol rates. All tumors with volumes of 25 mi or less remained locally con
trolled, compared with 56% of tumors larger than 25 mi (p = 0.02); 94% of p
atients without brainstem involvement did not experience recurrence; in pat
ients with brainstem involvement land dose reduction because of brainstem t
olerance constraints) the authors achieved a tumor control rate of 53% (p =
0.04). Three patients died of their disease, and one died of intercurrent
disease. Actuarial 5-year survival rates were 100% for patients with chondr
osarcoma and 79% for patients with chordoma. Grade 3 and 4 late toxicities
were observed in four patients (7%) and were symptomatic in three (5%).
Conclusions. High-dose proton RT offers excellent chances of lasting tumor
control and survival, with acceptable risks. In this series all small- and
medium-sized tumors with no demonstrable brainstem involvement have been co
ntrolled; all such patients are alive. Surgical debulking enhanced delivery
of full tumoricidal doses, but even patients with large tumors and disease
abutting crucial normal structures benefited.